CA2602522C - Method of treating skin ulcers using oxidative reductive potential water solution - Google Patents
Method of treating skin ulcers using oxidative reductive potential water solution Download PDFInfo
- Publication number
- CA2602522C CA2602522C CA2602522A CA2602522A CA2602522C CA 2602522 C CA2602522 C CA 2602522C CA 2602522 A CA2602522 A CA 2602522A CA 2602522 A CA2602522 A CA 2602522A CA 2602522 C CA2602522 C CA 2602522C
- Authority
- CA
- Canada
- Prior art keywords
- water solution
- orp water
- solution
- ulcer
- orp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 560
- 230000001590 oxidative effect Effects 0.000 title claims abstract description 31
- 230000002829 reductive effect Effects 0.000 title claims description 39
- 206010040943 Skin Ulcer Diseases 0.000 title abstract description 130
- 231100000019 skin ulcer Toxicity 0.000 title abstract description 113
- 238000000034 method Methods 0.000 title abstract description 105
- 208000025865 Ulcer Diseases 0.000 claims description 102
- 231100000397 ulcer Toxicity 0.000 claims description 96
- 239000000203 mixture Substances 0.000 claims description 79
- 239000000460 chlorine Substances 0.000 claims description 47
- 229910052801 chlorine Inorganic materials 0.000 claims description 47
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 44
- -1 hypochlorite ions Chemical class 0.000 claims description 26
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 claims description 21
- 208000008960 Diabetic foot Diseases 0.000 claims description 19
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims description 13
- 239000005708 Sodium hypochlorite Substances 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Inorganic materials Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 claims description 9
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 3
- 230000009467 reduction Effects 0.000 abstract description 60
- 239000000243 solution Substances 0.000 description 501
- 208000027418 Wounds and injury Diseases 0.000 description 93
- 238000011282 treatment Methods 0.000 description 92
- 206010052428 Wound Diseases 0.000 description 91
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 84
- 210000004027 cell Anatomy 0.000 description 84
- 238000009472 formulation Methods 0.000 description 62
- 238000006722 reduction reaction Methods 0.000 description 61
- 241000894007 species Species 0.000 description 57
- 210000001519 tissue Anatomy 0.000 description 56
- 239000012266 salt solution Substances 0.000 description 50
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 49
- 210000003630 histaminocyte Anatomy 0.000 description 47
- 208000015181 infectious disease Diseases 0.000 description 44
- 238000001356 surgical procedure Methods 0.000 description 44
- 238000002266 amputation Methods 0.000 description 42
- 230000000694 effects Effects 0.000 description 34
- 238000002360 preparation method Methods 0.000 description 33
- 239000000758 substrate Substances 0.000 description 31
- 210000003491 skin Anatomy 0.000 description 30
- 239000011780 sodium chloride Substances 0.000 description 30
- 206010012601 diabetes mellitus Diseases 0.000 description 29
- 229920000642 polymer Polymers 0.000 description 29
- 239000002562 thickening agent Substances 0.000 description 29
- 230000000813 microbial effect Effects 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 239000000427 antigen Substances 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 23
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 23
- 102000036639 antigens Human genes 0.000 description 23
- 108091007433 antigens Proteins 0.000 description 23
- 239000003795 chemical substances by application Substances 0.000 description 23
- 238000001804 debridement Methods 0.000 description 22
- 230000035876 healing Effects 0.000 description 22
- 239000000499 gel Substances 0.000 description 21
- 230000003472 neutralizing effect Effects 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 19
- 241000894006 Bacteria Species 0.000 description 18
- 108090000695 Cytokines Proteins 0.000 description 18
- 241000700605 Viruses Species 0.000 description 18
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 18
- 238000005868 electrolysis reaction Methods 0.000 description 18
- 150000002500 ions Chemical class 0.000 description 18
- 230000008569 process Effects 0.000 description 18
- 230000003247 decreasing effect Effects 0.000 description 17
- 239000000463 material Substances 0.000 description 17
- 208000003790 Foot Ulcer Diseases 0.000 description 16
- 230000001580 bacterial effect Effects 0.000 description 16
- 239000007844 bleaching agent Substances 0.000 description 16
- 230000028327 secretion Effects 0.000 description 16
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 15
- 102000004127 Cytokines Human genes 0.000 description 15
- 229920000153 Povidone-iodine Polymers 0.000 description 15
- 229920002125 Sokalan® Polymers 0.000 description 15
- 230000002411 adverse Effects 0.000 description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 244000005700 microbiome Species 0.000 description 15
- 239000001301 oxygen Substances 0.000 description 15
- 229910052760 oxygen Inorganic materials 0.000 description 15
- 229960001621 povidone-iodine Drugs 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 14
- 241000700159 Rattus Species 0.000 description 14
- 206010040047 Sepsis Diseases 0.000 description 14
- 230000000845 anti-microbial effect Effects 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 210000002683 foot Anatomy 0.000 description 14
- 239000003014 ion exchange membrane Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 241000191967 Staphylococcus aureus Species 0.000 description 13
- 230000023753 dehiscence Effects 0.000 description 13
- 230000001771 impaired effect Effects 0.000 description 13
- 238000002156 mixing Methods 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000004744 fabric Substances 0.000 description 12
- 230000001338 necrotic effect Effects 0.000 description 12
- 230000001603 reducing effect Effects 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 11
- 241000233866 Fungi Species 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 11
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 11
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 11
- 239000003242 anti bacterial agent Substances 0.000 description 11
- 238000004140 cleaning Methods 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 238000004659 sterilization and disinfection Methods 0.000 description 11
- 241000222122 Candida albicans Species 0.000 description 10
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 10
- 230000002354 daily effect Effects 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 238000003973 irrigation Methods 0.000 description 10
- 210000002414 leg Anatomy 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 238000002791 soaking Methods 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 201000002282 venous insufficiency Diseases 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 241000193830 Bacillus <bacterium> Species 0.000 description 9
- 239000004155 Chlorine dioxide Substances 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 229940095731 candida albicans Drugs 0.000 description 9
- 235000019398 chlorine dioxide Nutrition 0.000 description 9
- 230000002262 irrigation Effects 0.000 description 9
- 239000002243 precursor Substances 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 229910001415 sodium ion Inorganic materials 0.000 description 9
- 238000011200 topical administration Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 210000003414 extremity Anatomy 0.000 description 8
- 239000000017 hydrogel Substances 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 7
- 241000194032 Enterococcus faecalis Species 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 206010063560 Excessive granulation tissue Diseases 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 241000191938 Micrococcus luteus Species 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 239000000645 desinfectant Substances 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 229940032049 enterococcus faecalis Drugs 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 210000001126 granulation tissue Anatomy 0.000 description 7
- 229960001340 histamine Drugs 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 210000003141 lower extremity Anatomy 0.000 description 7
- 206010033675 panniculitis Diseases 0.000 description 7
- 150000002978 peroxides Chemical class 0.000 description 7
- 210000004304 subcutaneous tissue Anatomy 0.000 description 7
- 206010007882 Cellulitis Diseases 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 206010017711 Gangrene Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 206010028851 Necrosis Diseases 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 241000607715 Serratia marcescens Species 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 239000003710 calcium ionophore Substances 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 230000000249 desinfective effect Effects 0.000 description 6
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 230000002906 microbiologic effect Effects 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 230000017074 necrotic cell death Effects 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000000770 proinflammatory effect Effects 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 210000003371 toe Anatomy 0.000 description 6
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 5
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 5
- 108020005124 DNA Adducts Proteins 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 206010034576 Peripheral ischaemia Diseases 0.000 description 5
- 108091006629 SLC13A2 Proteins 0.000 description 5
- 241000191940 Staphylococcus Species 0.000 description 5
- 241000191963 Staphylococcus epidermidis Species 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000002421 anti-septic effect Effects 0.000 description 5
- 238000004061 bleaching Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 229940098803 hibiclens Drugs 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 5
- 201000001119 neuropathy Diseases 0.000 description 5
- 230000007823 neuropathy Effects 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 4
- 241000588626 Acinetobacter baumannii Species 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 206010062542 Arterial insufficiency Diseases 0.000 description 4
- 241000606124 Bacteroides fragilis Species 0.000 description 4
- 241000222178 Candida tropicalis Species 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 241000606768 Haemophilus influenzae Species 0.000 description 4
- 241000588915 Klebsiella aerogenes Species 0.000 description 4
- 241000588747 Klebsiella pneumoniae Species 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 241000588770 Proteus mirabilis Species 0.000 description 4
- 241000191984 Staphylococcus haemolyticus Species 0.000 description 4
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 4
- 241000193998 Streptococcus pneumoniae Species 0.000 description 4
- 241000193996 Streptococcus pyogenes Species 0.000 description 4
- 102100028748 Transportin-1 Human genes 0.000 description 4
- 238000005299 abrasion Methods 0.000 description 4
- 206010000269 abscess Diseases 0.000 description 4
- 238000012387 aerosolization Methods 0.000 description 4
- 210000003423 ankle Anatomy 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000000889 atomisation Methods 0.000 description 4
- 238000011888 autopsy Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229940092559 enterobacter aerogenes Drugs 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 229940047650 haemophilus influenzae Drugs 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000002663 nebulization Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 230000033116 oxidation-reduction process Effects 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 238000007632 sclerotherapy Methods 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 229940037649 staphylococcus haemolyticus Drugs 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 231100000057 systemic toxicity Toxicity 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 241000588749 Klebsiella oxytoca Species 0.000 description 3
- 208000005230 Leg Ulcer Diseases 0.000 description 3
- 208000034486 Multi-organ failure Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010031252 Osteomyelitis Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229920000297 Rayon Polymers 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 241000192087 Staphylococcus hominis Species 0.000 description 3
- 108010059993 Vancomycin Proteins 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229960005475 antiinfective agent Drugs 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 230000032677 cell aging Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000013626 chemical specie Substances 0.000 description 3
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011443 conventional therapy Methods 0.000 description 3
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- UQSQSQZYBQSBJZ-UHFFFAOYSA-N fluorosulfonic acid Chemical compound OS(F)(=O)=O UQSQSQZYBQSBJZ-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 229920001903 high density polyethylene Polymers 0.000 description 3
- 239000004700 high-density polyethylene Substances 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000001926 lymphatic effect Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 230000000474 nursing effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 230000000250 revascularization Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000036303 septic shock Effects 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 231100000041 toxicology testing Toxicity 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 230000036269 ulceration Effects 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 3
- 229960003165 vancomycin Drugs 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- RFIMISVNSAUMBU-UHFFFAOYSA-N 2-(hydroxymethyl)-2-(prop-2-enoxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC=C RFIMISVNSAUMBU-UHFFFAOYSA-N 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- QNGVNLMMEQUVQK-UHFFFAOYSA-N 4-n,4-n-diethylbenzene-1,4-diamine Chemical compound CCN(CC)C1=CC=C(N)C=C1 QNGVNLMMEQUVQK-UHFFFAOYSA-N 0.000 description 2
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 2
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 241000589291 Acinetobacter Species 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 208000033386 Buerger disease Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 206010060803 Diabetic foot infection Diseases 0.000 description 2
- RUPBZQFQVRMKDG-UHFFFAOYSA-M Didecyldimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC RUPBZQFQVRMKDG-UHFFFAOYSA-M 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 206010049927 Dry gangrene Diseases 0.000 description 2
- 241000194031 Enterococcus faecium Species 0.000 description 2
- 241000194029 Enterococcus hirae Species 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 206010016717 Fistula Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010021784 Infected skin ulcer Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- 241000186366 Mycobacterium bovis Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 102100027654 Transcription factor PU.1 Human genes 0.000 description 2
- 208000000558 Varicose Ulcer Diseases 0.000 description 2
- 206010046996 Varicose vein Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 206010001584 alcohol abuse Diseases 0.000 description 2
- 208000025746 alcohol use disease Diseases 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 238000001266 bandaging Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000002800 charge carrier Substances 0.000 description 2
- MAYPHUUCLRDEAZ-UHFFFAOYSA-N chlorine peroxide Inorganic materials ClOOCl MAYPHUUCLRDEAZ-UHFFFAOYSA-N 0.000 description 2
- 201000002816 chronic venous insufficiency Diseases 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229960000265 cromoglicic acid Drugs 0.000 description 2
- 229940109248 cromoglycate Drugs 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000617 effect on degranulation Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 208000024711 extrinsic asthma Diseases 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 229920002313 fluoropolymer Polymers 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000008076 immune mechanism Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940113601 irrigation solution Drugs 0.000 description 2
- 210000000281 joint capsule Anatomy 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 229920001684 low density polyethylene Polymers 0.000 description 2
- 239000004702 low-density polyethylene Substances 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000243 mutagenic effect Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000008789 oxidative DNA damage Effects 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 238000009258 post-therapy Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 108010008929 proto-oncogene protein Spi-1 Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000002964 rayon Substances 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 229940072768 sodium chloride irrigation solution Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000011301 standard therapy Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 239000012209 synthetic fiber Substances 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 210000002465 tibial artery Anatomy 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 101710187886 60S ribosomal protein L30 Proteins 0.000 description 1
- 102100040768 60S ribosomal protein L32 Human genes 0.000 description 1
- CGLVZFOCZLHKOH-UHFFFAOYSA-N 8,18-dichloro-5,15-diethyl-5,15-dihydrodiindolo(3,2-b:3',2'-m)triphenodioxazine Chemical compound CCN1C2=CC=CC=C2C2=C1C=C1OC3=C(Cl)C4=NC(C=C5C6=CC=CC=C6N(C5=C5)CC)=C5OC4=C(Cl)C3=NC1=C2 CGLVZFOCZLHKOH-UHFFFAOYSA-N 0.000 description 1
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical class C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108010001781 Apligraf Proteins 0.000 description 1
- 208000036490 Arterial inflammations Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 241000353754 Bacillus subtilis subsp. niger Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical class [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical class ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 241001574013 Collogenes Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 244000187656 Eucalyptus cornuta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 102100038006 High affinity immunoglobulin epsilon receptor subunit alpha Human genes 0.000 description 1
- 108050001540 High affinity immunoglobulin epsilon receptor subunit beta Proteins 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 101000726740 Homo sapiens Homeobox protein cut-like 1 Proteins 0.000 description 1
- 101000761460 Homo sapiens Protein CASP Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 208000035901 Ischaemic ulcer Diseases 0.000 description 1
- 241000500804 Klebsiella oxytoca 20 Species 0.000 description 1
- 241000588754 Klebsiella sp. Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 206010024404 Leukostasis Diseases 0.000 description 1
- 229920010126 Linear Low Density Polyethylene (LLDPE) Polymers 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 208000000185 Localized scleroderma Diseases 0.000 description 1
- 102000034655 MIF Human genes 0.000 description 1
- 108060004872 MIF Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 206010027982 Morphoea Diseases 0.000 description 1
- 206010028400 Mutagenic effect Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010031256 Osteomyelitis chronic Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035039 Piloerection Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102100024933 Protein CASP Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 229920001131 Pulp (paper) Polymers 0.000 description 1
- 206010037569 Purulent discharge Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000012180 RNAeasy kit Methods 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 230000010757 Reduction Activity Effects 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- NSOXQYCFHDMMGV-UHFFFAOYSA-N Tetrakis(2-hydroxypropyl)ethylenediamine Chemical compound CC(O)CN(CC(C)O)CCN(CC(C)O)CC(C)O NSOXQYCFHDMMGV-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044546 Traumatic ulcer Diseases 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000569 acute exposure Toxicity 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 231100000899 acute systemic toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229940086737 allyl sucrose Drugs 0.000 description 1
- NLKOSPLGBAHDND-UHFFFAOYSA-N aluminum chromium(3+) cobalt(2+) oxygen(2-) Chemical compound [O--].[O--].[O--].[O--].[Al+3].[Cr+3].[Co++] NLKOSPLGBAHDND-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000003447 amputation stump Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 210000003555 cloaca Anatomy 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 229940072645 coumadin Drugs 0.000 description 1
- 150000001925 cycloalkenes Chemical class 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 1
- 210000004262 dental pulp cavity Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000007682 dermal toxicity Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- UJKWLAZYSLJTKA-UHFFFAOYSA-N edma Chemical compound O1CCOC2=CC(CC(C)NC)=CC=C21 UJKWLAZYSLJTKA-UHFFFAOYSA-N 0.000 description 1
- 238000002283 elective surgery Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000012282 endovascular technique Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000027950 fever generation Effects 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 102000047486 human GAPDH Human genes 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000002727 hyperosmolar Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000008752 local inflammatory process Effects 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 238000007433 macroscopic evaluation Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000000479 mitotic spindle apparatus Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 206010033072 otitis externa Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- LCFBCKSQWVQIBY-QSVWIEALSA-N oxyclipine Chemical compound CN1CCC[C@H](C1)OC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1 LCFBCKSQWVQIBY-QSVWIEALSA-N 0.000 description 1
- 229950004511 oxyclipine Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000005371 pilomotor reflex Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920005646 polycarboxylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000006254 rheological additive Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 208000016997 secondary vasculitis Diseases 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003330 sporicidal effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical group OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000009959 type I hypersensitivity Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 208000037997 venous disease Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 239000012873 virucide Substances 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0088—Liquid substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/44—Applying ionised fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Radiology & Medical Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Treatment Of Water By Oxidation Or Reduction (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66436105P | 2005-03-23 | 2005-03-23 | |
| US60/664,361 | 2005-03-23 | ||
| US66710105P | 2005-03-31 | 2005-03-31 | |
| US60/667,101 | 2005-03-31 | ||
| US67688305P | 2005-05-02 | 2005-05-02 | |
| US60/676,883 | 2005-05-02 | ||
| US73074305P | 2005-10-27 | 2005-10-27 | |
| US60/730,743 | 2005-10-27 | ||
| US76056706P | 2006-01-20 | 2006-01-20 | |
| US76064506P | 2006-01-20 | 2006-01-20 | |
| US76063506P | 2006-01-20 | 2006-01-20 | |
| US76055706P | 2006-01-20 | 2006-01-20 | |
| US60/760,635 | 2006-01-20 | ||
| US60/760,557 | 2006-01-20 | ||
| US60/760,567 | 2006-01-20 | ||
| US60/760,645 | 2006-01-20 | ||
| PCT/US2006/011252 WO2006102681A2 (en) | 2005-03-23 | 2006-03-23 | Method of treating skin ulcers using oxidative reductive potential water solution |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2602522A1 CA2602522A1 (en) | 2006-09-28 |
| CA2602522C true CA2602522C (en) | 2014-09-09 |
Family
ID=36694050
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2602522A Active CA2602522C (en) | 2005-03-23 | 2006-03-23 | Method of treating skin ulcers using oxidative reductive potential water solution |
| CA2602411A Active CA2602411C (en) | 2005-03-23 | 2006-03-23 | Method of treating second and third degree burns using oxidative reductive potential water solution |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2602411A Active CA2602411C (en) | 2005-03-23 | 2006-03-23 | Method of treating second and third degree burns using oxidative reductive potential water solution |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8840873B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1863502B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5816405B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR101523091B1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2006226750B2 (cg-RX-API-DMAC7.html) |
| BR (2) | BRPI0609429B8 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2602522C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2701153T3 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2007011709A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2006102680A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6702949B2 (en) | 1997-10-24 | 2004-03-09 | Microdiffusion, Inc. | Diffuser/emulsifier for aquaculture applications |
| NO20043150D0 (no) * | 2004-07-23 | 2004-07-23 | Ntnu Technology Transfer As | "Fremgangsmate og utstyr for varmegjenvining" |
| EP1863502B1 (en) | 2005-03-23 | 2018-09-12 | Sonoma Pharmaceuticals, Inc. | Method of treating skin ulcers using oxidative reductive potential water solution |
| AU2012241151B2 (en) * | 2005-05-02 | 2016-02-04 | Oculus Innovative Sciences, Inc. | Method of using oxidative reductive potential water solution in dental applications |
| US9498548B2 (en) | 2005-05-02 | 2016-11-22 | Oculus Innovative Sciences, Inc. | Method of using oxidative reductive potential water solution in dental applications |
| PL1945576T3 (pl) * | 2005-10-28 | 2013-04-30 | Apr Nanotechnologies S A | Urządzenie zawierające elektrodę z nanopowłoką do przygotowywania wysoce trwałego roztworu wodnego i sposób wytwarzania tego roztworu wodnego |
| EP1993571B1 (en) | 2006-01-20 | 2018-07-25 | Sonoma Pharmaceuticals, Inc. | Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution |
| US20080014289A1 (en) * | 2006-07-12 | 2008-01-17 | Jianping Li | Vehicle and method for treating and preventing acne vulgaris and exfoliating the skin hypohalous acids |
| WO2008040020A2 (en) * | 2006-09-28 | 2008-04-03 | Puricore, Inc. | Apparatus and method for wound, cavity, and bone treatment |
| AU2007349224B2 (en) | 2006-10-25 | 2014-04-03 | Revalesio Corporation | Methods of wound care and treatment |
| JP5306214B2 (ja) | 2006-10-25 | 2013-10-02 | リバルシオ コーポレイション | 混合装置 |
| US8609148B2 (en) | 2006-10-25 | 2013-12-17 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
| US8784897B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
| US8445546B2 (en) | 2006-10-25 | 2013-05-21 | Revalesio Corporation | Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures |
| US8591957B2 (en) | 2006-10-25 | 2013-11-26 | Revalesio Corporation | Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution |
| US8784898B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of wound care and treatment |
| WO2008064272A2 (en) * | 2006-11-20 | 2008-05-29 | Promedtek, Inc. | Method of treating a severe diabetic ulcer |
| US9999635B2 (en) | 2007-01-16 | 2018-06-19 | Realm Therapeutics, Inc. | Methods and compositions for treating inflammatory disorders |
| WO2008089268A2 (en) * | 2007-01-16 | 2008-07-24 | Puricore, Inc. | Methods and compositions for treating conditions associated with infection and/or inflammation |
| EP2111252A4 (en) * | 2007-01-31 | 2010-12-01 | Adam Heller | MANAGEMENT OF PAIN BY ELECTROCHEMICAL PATHWAY |
| ES2524152T3 (es) | 2007-04-25 | 2014-12-04 | Apr Nanotechnologies S.A. | Agua electrolítica altamente estable con ancho de línea media de RMN reducido |
| AU2008280437B2 (en) * | 2007-07-26 | 2012-11-29 | Azad Pharma Ag | Pharmaceutical preparations comprising electrochemically activated hypochlorite solutions |
| US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US9486481B2 (en) | 2007-10-30 | 2016-11-08 | Reoxcyn Discoveries Group, Inc. | Method of modulating fatty acid mobilization and oxidation |
| ITMI20080114A1 (it) * | 2008-01-25 | 2009-07-26 | Gian Battista Ceresa | Formulazioni topiche in forma di gel acquosi per il trattamento di dermatite atopica o come veicoli per la somministrazione transdermica di farmaci |
| US20090198199A1 (en) * | 2008-02-01 | 2009-08-06 | Drug Enhancement Company Of America, Llc | Inert container and dispenser |
| WO2009134929A2 (en) | 2008-05-01 | 2009-11-05 | Revalesio Corporation | Compositions and methods for treating digestive disorders |
| JP5596907B2 (ja) * | 2008-06-06 | 2014-09-24 | 大日精化工業株式会社 | 創傷治療用組成物の製造方法 |
| WO2010011927A1 (en) * | 2008-07-25 | 2010-01-28 | Noventis, Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
| KR101781229B1 (ko) | 2009-06-15 | 2017-09-22 | 오클루스 이노바티브 사이언시즈 인코포레이티드 | 차아염소산을 함유하는 용액 및 그의 사용 방법 |
| WO2010146460A1 (en) * | 2009-06-17 | 2010-12-23 | Apr Nanotechnologies S.A. | Methods of treating outer eye disorders using high orp acid water and compositions thereof |
| MX2012001415A (es) * | 2009-07-30 | 2012-06-19 | Oculus Innovative Sciences Inc | Formulacion de hidrogel que comprende agua con potencial de oxidacion-reducció. |
| JP6075732B2 (ja) | 2010-04-13 | 2017-02-08 | ケーシーアイ ライセンシング インク | 反応性成分を含む組成物ならびに創傷被覆材、装置および方法 |
| EP2558156B1 (en) | 2010-04-14 | 2017-11-01 | Hypo-Stream Limited | Device for preparing dilute disinfectant solution |
| JP6026998B2 (ja) | 2010-05-07 | 2016-11-16 | リバルシオ コーポレイション | 生理的パフォーマンスおよび回復時間を強化するための組成物および方法 |
| CA2989896C (en) | 2010-07-22 | 2021-02-09 | Reven Pharmaceuticals, Inc. | Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution |
| EA201300228A1 (ru) | 2010-08-12 | 2013-06-28 | Ревалезио Корпорейшн | Композиции и способы лечения таупатии |
| CN103796515B (zh) | 2011-03-18 | 2017-05-03 | 瑞尔姆治疗股份有限公司 | 稳定的次卤酸溶液 |
| US9381214B2 (en) | 2011-03-18 | 2016-07-05 | Puricore, Inc. | Methods for treating skin irritation |
| US11452778B2 (en) | 2011-03-18 | 2022-09-27 | Urgo Us, Inc. | Stabilized hypohalous acid solutions |
| CN102389743A (zh) * | 2011-06-14 | 2012-03-28 | 陈旭良 | 一种抑菌医用湿化液的组方 |
| US9669041B2 (en) | 2011-10-27 | 2017-06-06 | Novan, Inc. | Nitric oxide releasing bath compositions and methods of using the same |
| CN104903494B (zh) * | 2012-09-21 | 2017-11-03 | 瑞奥可塞恩探索集团有限公司 | 用于电解液体的电池 |
| EP2999341B1 (en) | 2013-05-22 | 2018-11-28 | Sonoma Pharmaceuticals, Inc. | Stabilized hypochlorous acid solution and use thereof |
| US20150099010A1 (en) * | 2013-10-07 | 2015-04-09 | Reoxcyn Discoveries Group, Inc | Redox signaling gel formulation |
| US9597353B2 (en) | 2013-10-24 | 2017-03-21 | Reoxcyn Discoveries Group, Inc. | Redox signaling gel formulation |
| CA2929150A1 (en) * | 2013-10-29 | 2015-05-07 | Hypo-Stream Limited | Anti-inflammatory solution comprising sodium hypochlorite |
| WO2015200827A1 (en) * | 2014-06-27 | 2015-12-30 | Brown Solomon | Compositions and methods for mixing and applying mixed oxidant compositions for dairy animal treatment |
| MX374040B (es) | 2014-08-08 | 2020-04-30 | Juan Manuel Nunez Montalvo | Aparato y método para la producción de una solución de súper oxidación ácida y una solución alcalina con flujos independientes con orp a partir de soluciones acuosas. |
| EP3229900A4 (en) * | 2014-12-10 | 2018-11-14 | Devicefarm Inc. | Onychomycosis treatment apparatus and method |
| HK1245641A1 (zh) | 2014-12-16 | 2018-08-31 | Realm Therapeutics, Inc. | 次氯酸制剂及治疗皮肤病的方法 |
| US10617716B2 (en) * | 2014-12-16 | 2020-04-14 | Urgo Us, Inc. | Hypochlorous acid formulations and methods for treating skin conditions |
| US10094030B2 (en) | 2015-02-03 | 2018-10-09 | Tipul Biotechnology, LLC | Devices and methods for electrolytic production of disinfectant solution from salt solution in a container |
| US20160317577A1 (en) * | 2015-05-01 | 2016-11-03 | Reoxcyn Discoveries Group, Inc. | Electrolyzed saline redox-balanced compositions and methods for treating skin conditions |
| US20160331779A1 (en) | 2015-05-11 | 2016-11-17 | Novabay Pharmaceuticals, Inc. | Method of inactivating toxins using oxidative chlorine species |
| US10485827B2 (en) | 2016-01-19 | 2019-11-26 | Rdg Holdings, Inc. | Topical eye serum compositions, methods or preparing, and methods of use |
| US11857674B2 (en) | 2016-05-18 | 2024-01-02 | Reoxcyn, Llc | Lubricant formulations |
| US9474768B1 (en) | 2016-05-18 | 2016-10-25 | Reoxcyn Discoveries Group, Inc. | Lubricant formulations |
| WO2018015570A1 (en) * | 2016-07-22 | 2018-01-25 | Koninklijke Philips N.V. | Administration of oral care antimicrobials |
| EP3554563A1 (en) | 2016-12-15 | 2019-10-23 | Adept Water Technologies A/S | Device for producing aqueous liquid having free available chlorine (fac) |
| CN107049934A (zh) * | 2017-03-10 | 2017-08-18 | 山西纳安生物科技有限公司 | 一种调节女性阴道微生态的妇科阴道洗液及其制备方法 |
| CA3088373A1 (en) | 2018-01-14 | 2019-07-18 | Collidion, Inc. | Compositions, kits, methods and uses for cleaning, disinfecting, sterilizing and/or treating |
| BR112021023632A2 (pt) * | 2019-06-04 | 2022-04-19 | Thirty Respiratory Ltd | Métodos e composições para gerar óxido nítrico e usos do mesmo para entregar óxido nítrico através do trato respiratório |
| BR112021025195A2 (pt) * | 2019-06-14 | 2022-03-03 | Collidion Inc | Composições, kits, métodos e usos para prevenir o crescimento microbiano |
| US11707433B2 (en) * | 2019-09-01 | 2023-07-25 | Pathway Development Llc | Methods and compositions for treating diabetic foot ulcers |
| CN116322332A (zh) * | 2020-10-09 | 2023-06-23 | 株式会社Acenet | 抗病原体药剂、抗菌剂、抗病毒剂、病原体处理装置、抗病原体药剂的制造方法、抗菌方法、病毒失活方法及病原体处理方法 |
| EP4056148A1 (en) * | 2021-03-09 | 2022-09-14 | Qianxun Everything (Shenzhen) Technology Co., Ltd. | Pet wound spraying apparatus |
| US12419332B2 (en) | 2021-06-11 | 2025-09-23 | Strategic Resource Optimization, Inc. | Electrolytic methods and systems for generating temper fluid |
| CN116672492A (zh) * | 2023-06-05 | 2023-09-01 | 吉林大学 | 一种应用于糖尿病细菌感染创面愈合的液体敷料及其制备方法 |
Family Cites Families (370)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3066095A (en) | 1959-09-30 | 1962-11-27 | Hagan Chemicals & Controls Inc | Water purification agents and method of using same |
| GB1367067A (en) | 1970-10-06 | 1974-09-18 | Wilkinson Sword Ltd | Compositions containing a source of hypochlorite ions |
| GB1422795A (en) | 1972-05-31 | 1976-01-28 | Bunyan J | Antiseptic and non-toxic substance and a method of making the same |
| US3975246A (en) | 1973-06-09 | 1976-08-17 | Sachs-Systemtechnik Gmbh | Method of disinfecting water |
| US3975247A (en) | 1974-01-23 | 1976-08-17 | Stralser Bernard J | Treating sewage and recovering usable water and solids |
| DE2442078A1 (de) | 1974-09-03 | 1976-03-18 | Sachs Systemtechnik Gmbh | Verfahren und vorrichtung zur entkeimung und entgiftung von fluessigkeiten mittels anodischer oxydation unter zusatz von silber |
| US3949742A (en) * | 1974-09-20 | 1976-04-13 | Frigitronics, Inc. | Medical dressing |
| DE2607906A1 (de) | 1976-02-26 | 1977-09-01 | Hans Einhell Inh Josef Thannhu | Elektrolysezelle fuer die behandlung von wasser |
| US4146578A (en) | 1977-12-27 | 1979-03-27 | Olin Corporation | Hypochlorous acid process |
| US4190638A (en) | 1978-06-07 | 1980-02-26 | Ppg Industries, Inc. | Production of hypochlorous acid |
| US4242446A (en) | 1978-07-26 | 1980-12-30 | Coulter Electronics, Inc. | Method for determining a substance in a biological fluid and reagent combination for use in the method |
| BR7908937A (pt) | 1978-12-06 | 1981-06-30 | Svedman Paul | Dispositivo para tratamento de tecidos,por exemplo,pele |
| US4236992A (en) | 1979-08-06 | 1980-12-02 | Themy Constantinos D | High voltage electrolytic cell |
| JPS5684089U (cg-RX-API-DMAC7.html) | 1979-11-30 | 1981-07-07 | ||
| US4296103A (en) | 1980-08-08 | 1981-10-20 | Felipe Laso | Stabilized solution of chlorine oxides |
| DE3046324A1 (de) | 1980-12-09 | 1982-12-16 | Rudolf Dr.med. 6900 Heidelberg Anderson | Verfahren zur herstellung eines praeparates zur vernichtung von mikroben, welche die lunge befallen |
| US4670252A (en) | 1985-05-24 | 1987-06-02 | The Procter & Gamble Company | Treatment of oral diseases |
| JPH0731981B2 (ja) | 1985-07-10 | 1995-04-10 | 日本電気ホームエレクトロニクス株式会社 | Ｕ形バルブの加熱装置 |
| US4615937A (en) | 1985-09-05 | 1986-10-07 | The James River Corporation | Antimicrobially active, non-woven web used in a wet wiper |
| US4693832A (en) | 1985-11-27 | 1987-09-15 | Quantum Technologies, Inc. | Preparation of safe drinking water |
| US4970216A (en) | 1986-03-17 | 1990-11-13 | Richardson Vicks, Inc. | Skin treatment composition and method |
| US4666621A (en) | 1986-04-02 | 1987-05-19 | Sterling Drug Inc. | Pre-moistened, streak-free, lint-free hard surface wiping article |
| US4781974A (en) | 1986-04-23 | 1988-11-01 | James River Corporation | Antimicrobially active wet wiper |
| IT1207620B (it) | 1987-02-27 | 1989-05-25 | Castellini Spa | Metodo ed apparecchiatura per la stelizzazione a freddo di strumenti chirurgici in particolare per strumenti odontoiatrici |
| US5906810A (en) | 1987-03-17 | 1999-05-25 | Turner; Robert E. | Formulations and uses thereof in the prevention and treatment of oral lesions |
| US4767511A (en) | 1987-03-18 | 1988-08-30 | Aragon Pedro J | Chlorination and pH control system |
| US5388571A (en) | 1987-07-17 | 1995-02-14 | Roberts; Josephine A. | Positive-pressure ventilator system with controlled access for nebulizer component servicing |
| FI82808C (fi) | 1987-12-31 | 1991-04-25 | Etelae Haemeen Keuhkovammayhdi | Ultraljudfinfoerdelningsanordning. |
| JP2638611B2 (ja) * | 1988-06-17 | 1997-08-06 | 紀久雄 及川 | 安定化二酸化塩素水溶液の製造法 |
| DE3929411A1 (de) | 1988-09-22 | 1990-03-29 | Siegfried Natterer | Pharmazeutische zubereitung sowie verfahren zu ihrer herstellung |
| JPH0293088A (ja) | 1988-09-29 | 1990-04-03 | Permelec Electrode Ltd | 水電解方法及び装置 |
| US5037627A (en) | 1988-10-31 | 1991-08-06 | Olin Corporation | Hypochlorous acid process |
| US4979938A (en) | 1989-05-11 | 1990-12-25 | Iomed, Inc. | Method of iontophoretically treating acne, furuncles and like skin disorders |
| SE466196B (sv) | 1989-06-13 | 1992-01-13 | Pavel Voracek | Foerfarande och anordning foer elektrisk behandling av en elektrolytisk loesning samt loesningsfraktioner framstaellda enligt foerfarandet |
| US6638413B1 (en) | 1989-10-10 | 2003-10-28 | Lectro Press, Inc. | Methods and apparatus for electrolysis of water |
| US5271943A (en) | 1989-10-27 | 1993-12-21 | Scott Health Care | Wound gel compositions containing sodium chloride and method of using them |
| US5152757A (en) | 1989-12-14 | 1992-10-06 | Brigham And Women's Hospital | System for diagnosis and treatment of wounds |
| US5126057A (en) | 1990-01-22 | 1992-06-30 | Auburn Research Foundation | Disinfecting with N,N'-dihaloimidazolidin-4-ones |
| US5084011A (en) | 1990-01-25 | 1992-01-28 | Grady Daniel J | Method for oxygen therapy using hyperbarically oxygenated liquid |
| US5622848A (en) | 1990-05-23 | 1997-04-22 | Medical Discoveries, Inc. | Electrically hydrolyzed salines as microbiocides for in vitro treatment of contaminated fluids containing blood |
| US5334383A (en) | 1990-05-23 | 1994-08-02 | Medical Discoveries, Inc. | Electrically hydrolyzed salines as in vivo microbicides for treatment of cardiomyopathy and multiple sclerosis |
| US5128136A (en) | 1990-07-16 | 1992-07-07 | The Oregon Health Sciences University | Wound healing kit comprised of gelable collagen |
| US5244768A (en) | 1991-02-15 | 1993-09-14 | Fuji Xerox Co., Ltd. | Manufacturing process for an electrophotographic toner |
| GB2253860B (en) | 1991-03-12 | 1995-10-11 | Kirk And Charashvili Internati | The electrochemical treatment of water and a device for electrochemically treating water |
| JP3236315B2 (ja) | 1991-08-27 | 2001-12-10 | 修生 澄田 | 中間室を設けた純水電解槽 |
| US5152915A (en) | 1991-09-03 | 1992-10-06 | Olin Corporation | Recovery of dichlorine monoxide from hypochlorous acid solutions |
| US5636643A (en) | 1991-11-14 | 1997-06-10 | Wake Forest University | Wound treatment employing reduced pressure |
| EP0546964B1 (en) | 1991-12-10 | 1997-04-09 | TDK Corporation | An ultrasonic wave nebulizer |
| JP3247134B2 (ja) | 1991-12-27 | 2002-01-15 | 修生 澄田 | 純水の電解による水素イオンまたは水酸イオンと酸化還元物質が共存した液およびその製造方法 |
| JP2611080B2 (ja) | 1992-02-20 | 1997-05-21 | 英雄 早川 | 水の改質方法 |
| JP2615308B2 (ja) | 1992-02-20 | 1997-05-28 | 英雄 早川 | 水の改質方法 |
| US5622725A (en) | 1992-03-20 | 1997-04-22 | Alcide Corporation | Wound disinfection and repair |
| DE4391418T1 (de) | 1992-04-03 | 1994-05-05 | Bacir Vitold M | Vorrichtung zur elektrochemischen Behandlung von Wasser |
| US5287847A (en) | 1992-07-24 | 1994-02-22 | Vortran Medical Technology, Inc. | Universal nebulizer |
| US6544502B2 (en) | 1992-09-11 | 2003-04-08 | Wasatch Pharmaceutical Inc. | Skin treatment with a water soluble antibiotic dissolved in an electrolyzed water |
| JPH06206825A (ja) | 1992-12-11 | 1994-07-26 | Nippon Rooshiyon Kk | 白癬菌、湿疹等による皮膚病の治療剤及び 皮膚殺菌活性化剤 |
| JPH06182345A (ja) | 1992-12-21 | 1994-07-05 | Tonen Corp | 水浄化装置 |
| GB9227020D0 (en) | 1992-12-24 | 1993-02-17 | Solvay Interox Ltd | Microbicidual compositions |
| DE69409996T2 (de) | 1993-02-22 | 1999-01-14 | Nippon Intek Co., Ltd., Kawagoe, Saitama | Verfahren und Vorrichtung zur Erzeugung von elektrolytischem Wasser |
| JP2623204B2 (ja) | 1993-02-26 | 1997-06-25 | 英雄 早川 | 水の改質方法 |
| JPH06312183A (ja) | 1993-04-28 | 1994-11-08 | Shinko Pantec Co Ltd | 電解イオン水の製造方法及びそのための装置 |
| DE4317174A1 (de) | 1993-05-22 | 1994-11-24 | Bosch Gmbh Robert | Verbundsystem mit mindestens zwei anorganischen keramischen Schichten und Verfahren zu deren Herstellung |
| JPH06335685A (ja) | 1993-05-28 | 1994-12-06 | Funai Electric Co Ltd | イオン水生成器 |
| JP2652609B2 (ja) | 1993-05-31 | 1997-09-10 | ミズ株式会社 | 電解水生成装置 |
| JPH0710762A (ja) | 1993-06-25 | 1995-01-13 | Miura Denshi Kk | 口内炎用うがい水 |
| JP3325081B2 (ja) | 1993-06-28 | 2002-09-17 | 英雄 早川 | 水の浄化方法及びその装置 |
| DE69430196T2 (de) | 1993-06-29 | 2002-10-31 | Ponwell Enterprises Ltd., Hongkong | Spender |
| JP3458341B2 (ja) | 1993-07-12 | 2003-10-20 | 有限会社コヒーレントテクノロジー | 対イオンよりも水素イオン又は水酸イオンを過剰に含む洗浄水の製造方法及び得られた洗浄水 |
| JP3321256B2 (ja) | 1993-07-30 | 2002-09-03 | ミズ株式会社 | 貯水式電解水生成装置 |
| JP3504344B2 (ja) | 1993-08-31 | 2004-03-08 | 三浦電子株式会社 | 家畜皮膚疾患治療水 |
| JPH07104221A (ja) * | 1993-10-01 | 1995-04-21 | Tomey Technol Corp | コンタクトレンズの洗浄殺菌方法 |
| US5965452A (en) | 1996-07-09 | 1999-10-12 | Nanogen, Inc. | Multiplexed active biologic array |
| JP3500173B2 (ja) | 1993-12-01 | 2004-02-23 | ホシザキ電機株式会社 | 電解水製造装置 |
| JP3420820B2 (ja) | 1994-02-05 | 2003-06-30 | ペルメレック電極株式会社 | 電解酸性水製造方法及び製造装置 |
| JP3324260B2 (ja) | 1994-02-28 | 2002-09-17 | 宮▲崎▼ 浩司 | 隅棟瓦の葺設構造 |
| JP2830733B2 (ja) | 1994-03-25 | 1998-12-02 | 日本電気株式会社 | 電解水生成方法および電解水生成機構 |
| JP2737643B2 (ja) | 1994-03-25 | 1998-04-08 | 日本電気株式会社 | 電解活性水の生成方法および生成装置 |
| US5599438A (en) | 1994-03-25 | 1997-02-04 | Nec Corporation | Method for producing electrolyzed water |
| JP3468835B2 (ja) | 1994-05-09 | 2003-11-17 | ホシザキ電機株式会社 | 電解水生成装置 |
| JPH07323289A (ja) | 1994-05-30 | 1995-12-12 | Janome Sewing Mach Co Ltd | 超酸化水生成装置およびその方法 |
| JP3396853B2 (ja) | 1994-06-21 | 2003-04-14 | 有限会社コヒーレントテクノロジー | 水の製造方法及び得られた水 |
| JP2949322B2 (ja) | 1994-07-19 | 1999-09-13 | 株式会社アロンワールド | イオン水、その製造方法および製造装置 |
| US5858201A (en) | 1994-07-29 | 1999-01-12 | Toto, Ltd. | Strong acid sterilizing liquid containing hypochlorous acid at a low concentration, method and apparatus for generating same, and apparatus for generating and dispensing same |
| JPH0852476A (ja) | 1994-08-12 | 1996-02-27 | Janome Sewing Mach Co Ltd | 超酸化水生成装置 |
| JP3465367B2 (ja) | 1994-08-23 | 2003-11-10 | 東陶機器株式会社 | イオンリッチ水生成装置 |
| JPH0861788A (ja) | 1994-08-25 | 1996-03-08 | Kozo Yamanoi | 太陽熱温水器 |
| US5507932A (en) | 1994-08-26 | 1996-04-16 | Schlumberger Technology Corporation | Apparatus for electrolyzing fluids |
| US6117285A (en) | 1994-08-26 | 2000-09-12 | Medical Discoveries, Inc. | System for carrying out sterilization of equipment |
| JP3488294B2 (ja) | 1994-10-14 | 2004-01-19 | 忠正 中村 | 水の処理方法及び処理装置 |
| JP2857334B2 (ja) | 1994-10-18 | 1999-02-17 | 行正 佐藤 | 電解イオン水生成装置 |
| KR100227969B1 (ko) | 1994-10-20 | 1999-11-01 | 사카모토 시게토시 | 전해수 생성장치 |
| JPH08126873A (ja) | 1994-10-28 | 1996-05-21 | Nec Corp | 電子部品等の洗浄方法及び装置 |
| JP3181796B2 (ja) | 1994-10-28 | 2001-07-03 | 日本電気株式会社 | 電解水製造装置 |
| JP3181795B2 (ja) | 1994-10-28 | 2001-07-03 | オルガノ株式会社 | 電解水製造装置 |
| JPH08126886A (ja) | 1994-10-28 | 1996-05-21 | Japan Organo Co Ltd | 超純水の製造方法及び装置 |
| DE69506912T2 (de) | 1994-11-09 | 1999-05-27 | The Procter & Gamble Co., Cincinnati, Ohio | Mit einer wasser-in-lipid emulsion behandelte reinigungstücher |
| DK173485B1 (da) | 1994-12-02 | 2000-12-18 | Thure Barsoee Carnfeldt | Fremgangsmåde til desinfektion eller sterilisation af fødevarer, foderstoffer, maskineri og udstyr til fødevare- og foderst |
| JPH08164192A (ja) | 1994-12-15 | 1996-06-25 | Life Sapooto:Kk | 植物性の消臭剤 |
| EP0800388A4 (en) | 1995-01-06 | 2001-04-04 | Australian Biomedical Company | CONNECTIONS FOR VETERINAIRES AND MEDICAL USE |
| JPH08252310A (ja) | 1995-01-17 | 1996-10-01 | Miura Denshi Kk | 電解生成酸性水を用いた人工透析装置の洗浄殺菌方法およびその装置 |
| DE69602383T2 (de) | 1995-01-30 | 1999-09-16 | First Ocean Co., Ltd. | Vorrichtung einer zusammengesetzten Elektrode für die Elektrolyse von Wasser |
| US6007693A (en) | 1995-03-30 | 1999-12-28 | Bioquest | Spa halogen generator and method of operating |
| US5578022A (en) | 1995-04-12 | 1996-11-26 | Scherson; Daniel A. | Oxygen producing bandage and method |
| JP3313263B2 (ja) | 1995-04-15 | 2002-08-12 | 株式会社東芝 | 電解水生成方法及びその生成装置、半導体製造装置 |
| HU213450B (en) | 1995-04-26 | 1997-06-30 | Ladanyi Jozsef | Gel contains gelatin and process for producing it |
| JP2832171B2 (ja) | 1995-04-28 | 1998-12-02 | 信越半導体株式会社 | 半導体基板の洗浄装置および洗浄方法 |
| JPH08326124A (ja) | 1995-05-31 | 1996-12-10 | Isao Ueno | 洗浄器付便器 |
| US5871623A (en) | 1995-05-31 | 1999-02-16 | Rscecat, Usa, Inc. | Apparatus for electrochemical treatment of water and/or water solutions |
| US5792090A (en) | 1995-06-15 | 1998-08-11 | Ladin; Daniel | Oxygen generating wound dressing |
| JP3193295B2 (ja) | 1995-07-07 | 2001-07-30 | 株式会社日本トリム | 透析装置 |
| JPH0925236A (ja) | 1995-07-12 | 1997-01-28 | Koichiro Kameyama | 亜鉛含有アルカリ電解水 |
| JP3153473B2 (ja) | 1995-08-17 | 2001-04-09 | 株式会社カイゲン | 医療器具用消毒装置 |
| CN1148322C (zh) | 1996-10-18 | 2004-05-05 | 水株式会社 | 还原性电解水及其生成方法 |
| FR2740335B1 (fr) | 1995-10-26 | 1997-12-19 | Oreal | Utilisation de sel de lanthanide, de lithium, d'etain, de zinc, de manganese ou d'yttrium comme antagoniste de substance p |
| JP3312837B2 (ja) | 1995-11-30 | 2002-08-12 | アルプス電気株式会社 | イオン水製造装置及び製造方法並びに電解イオン水製造システム及び製造方法 |
| US5928491A (en) | 1996-01-23 | 1999-07-27 | Maruko & Co., Ltd. | Plant compatible electrolyte composition as well as electrolyte ionized water production device and methods |
| US5858202A (en) | 1996-01-30 | 1999-01-12 | Zenkoku-Mokko-Kikai-Kan, Inc. | Method for producing electrolytic water and apparatus for producing the same |
| JP3481761B2 (ja) | 1996-01-30 | 2003-12-22 | 忠正 中村 | 電解水の生成方法 |
| US5783052A (en) | 1996-03-11 | 1998-07-21 | Rscecat, Usa, Inc. | Electrochemical cell |
| US5635040A (en) | 1996-03-11 | 1997-06-03 | Rscecat, Usa, Inc. | Electrochemical cell |
| JP3785219B2 (ja) | 1996-03-27 | 2006-06-14 | ペルメレック電極株式会社 | 酸性水及びアルカリ性水の製造方法 |
| US5985110A (en) | 1996-03-28 | 1999-11-16 | Bakhir; Vitold M. | Apparatus for electrochemical treatment of water and/or water solutions |
| JP3716042B2 (ja) | 1996-04-24 | 2005-11-16 | ペルメレック電極株式会社 | 酸性水の製造方法及び電解槽 |
| CZ287999B6 (cs) | 1996-04-30 | 2001-03-14 | The Procter & Gamble Company | Hygienický výrobek pro čištění kůže a pevných povrchů a způsob jeho výroby |
| US5662625A (en) | 1996-05-06 | 1997-09-02 | Gwr Medical, L.L.P. | Pressure controllable hyperbaric device |
| JPH11169856A (ja) | 1996-06-04 | 1999-06-29 | Mizu Kk | 電解水生成装置 |
| US6028018A (en) | 1996-07-24 | 2000-02-22 | Kimberly-Clark Worldwide, Inc. | Wet wipes with improved softness |
| JPH1043764A (ja) | 1996-08-06 | 1998-02-17 | First Ocean Kk | 水電気分解用電極及びそれを用いて水を滅菌する方法 |
| US5728274A (en) | 1996-08-13 | 1998-03-17 | Hoshizaki Denki Kabushiki Kaisha | Production system of electrolyzed water |
| JP3408394B2 (ja) | 1996-08-27 | 2003-05-19 | 株式会社日本トリム | 電解水素溶存水の製造方法ならびにその製造装置 |
| JPH1080686A (ja) | 1996-09-09 | 1998-03-31 | Takazono Sangyo Kk | 強酸性水生成装置 |
| GB2316090B (en) | 1996-09-26 | 1998-12-23 | Julian Bryson | Method and apparatus for producing a sterilising solution |
| US6007696A (en) | 1996-09-28 | 1999-12-28 | Kabushiki Kaisha Toshiba | Apparatus and method for manufacturing electrolytic ionic water and washing method using electroyltic ionic water |
| GB2316091B (en) | 1996-10-23 | 1999-06-16 | Julian Bryson | Electrolytic treatment of aqueous salt solutions |
| US5728287A (en) | 1996-10-31 | 1998-03-17 | H2 O Technologies, Ltd. | Method and apparatus for generating oxygenated water |
| JPH1157720A (ja) | 1996-11-07 | 1999-03-02 | Honda Motor Co Ltd | 電解機能水、その製造方法及び製造装置 |
| JP3455035B2 (ja) | 1996-11-14 | 2003-10-06 | 株式会社東芝 | 電解イオン水生成装置及び半導体製造装置 |
| US5908707A (en) | 1996-12-05 | 1999-06-01 | The Procter & Gamble Company | Cleaning articles comprising a high internal phase inverse emulsion and a carrier with controlled absorbency |
| RU2119802C1 (ru) | 1996-12-18 | 1998-10-10 | Стерилокс Текнолоджиз, Инк. | Установка для электрохимической обработки жидкой среды (варианты) |
| JP3366986B2 (ja) | 1996-12-27 | 2003-01-14 | 高橋金属株式会社 | 洗浄水 |
| US5941859A (en) * | 1997-03-17 | 1999-08-24 | Lerman; Benjamin S. | Wound irrigation shield with fluid scavenging |
| RU2110483C1 (ru) | 1997-03-24 | 1998-05-10 | Стерилокс Текнолоджиз, Инк. | Устройство для электрохимической обработки воды |
| US5963435A (en) | 1997-03-25 | 1999-10-05 | Gianna Sweeney | Apparatus for coating metal with oxide |
| US5759478A (en) | 1997-03-27 | 1998-06-02 | Viskase Corporation | Mandrel structure for use in manufacture of cellulose food casing |
| JPH10286571A (ja) | 1997-04-16 | 1998-10-27 | Permelec Electrode Ltd | 酸性水及びアルカリ水製造用電解槽 |
| US5888528A (en) | 1997-05-19 | 1999-03-30 | Bernard Technologies, Inc. | Sustained release biocidal powders |
| JPH10314740A (ja) | 1997-05-19 | 1998-12-02 | Permelec Electrode Ltd | 酸性水製造用電解槽 |
| RO117540B1 (ro) | 1997-06-13 | 2002-04-30 | Scchimcomplex Sa Borzesti | Compozitie dezinfectanta-detergenta |
| US6093292A (en) | 1997-06-17 | 2000-07-25 | Shimadzu Corporation | Electrolyte producing apparatus with monitoring device |
| TW502130B (en) | 1997-06-17 | 2002-09-11 | Toshiba Corp | Cleaning method of substrate |
| RU2132821C1 (ru) | 1997-06-25 | 1999-07-10 | Стерилокс Текнолоджиз, Инк. | Устройство для электролитической обработки воды |
| EP0991852A2 (en) | 1997-06-27 | 2000-04-12 | Lynntech, Inc. | Method and apparatus for injecting hydrogen into a catalytic converter |
| US5964089A (en) | 1997-06-27 | 1999-10-12 | Lynntech, Inc | Diagnostics and control of an on board hydrogen generation and delivery system |
| US6143163A (en) | 1997-08-06 | 2000-11-07 | Permelec Electrode Ltd. | Method of water electrolysis |
| US5932171A (en) | 1997-08-13 | 1999-08-03 | Steris Corporation | Sterilization apparatus utilizing catholyte and anolyte solutions produced by electrolysis of water |
| US5944978A (en) | 1997-08-21 | 1999-08-31 | Omco Co., Ltd. | Cleaning method of an electrolyzed water forming apparatus and an electrolyzed water forming apparatus having mechanism for conducting the method |
| US5928488A (en) | 1997-08-26 | 1999-07-27 | David S. Newman | Electrolytic sodium sulfate salt splitter comprising a polymeric ion conductor |
| CA2270199C (en) | 1997-08-27 | 2005-08-09 | Miz Co., Ltd. | Electrolytic cell and electrolyzed water generating device |
| EP1041879B2 (en) | 1997-10-10 | 2012-03-21 | Pure Bioscience | Disinfectant and method of making |
| US6294073B1 (en) | 1997-10-22 | 2001-09-25 | Chemicoat & Co., Ltd. | Manufacturing method and apparatus of alkaline ionized water |
| CN1136153C (zh) | 1997-10-23 | 2004-01-28 | 星崎电机株式会社 | 电解水生成装置 |
| US20040131695A1 (en) | 1997-10-23 | 2004-07-08 | Radical Waters Ip (Pty) Ltd. | Use of an aqueous solution in the treatment of live animals |
| JPH10113664A (ja) | 1997-11-13 | 1998-05-06 | Aiken Kogyo Kk | 高電子活動度を有する殺菌水 |
| AU735234B2 (en) | 1997-12-04 | 2001-07-05 | Steris Corporation | Chemical modification of electrochemically activated water |
| JP4187181B2 (ja) | 1997-12-26 | 2008-11-26 | 森永乳業株式会社 | 物品の殺菌方法及び物品の包装方法 |
| US6171551B1 (en) | 1998-02-06 | 2001-01-09 | Steris Corporation | Electrolytic synthesis of peracetic acid and other oxidants |
| JPH11226092A (ja) | 1998-02-12 | 1999-08-24 | Trp:Kk | 医療用具の殺菌洗浄方法およびその装置 |
| JPH11239790A (ja) | 1998-02-25 | 1999-09-07 | Yoshiya Okazaki | 電解水生成装置およびその洗浄方法 |
| US5948220A (en) | 1998-02-27 | 1999-09-07 | Hoshizaki Denki Kabushiki Kaisha | Production system of electrolyzed water |
| TW477833B (en) | 1998-02-27 | 2002-03-01 | Amano Corp | Apparatus for producing electrolytic water |
| JP3896210B2 (ja) | 1998-03-06 | 2007-03-22 | ホシザキ電機株式会社 | 電解水生成装置 |
| JP3443310B2 (ja) | 1998-03-09 | 2003-09-02 | ホシザキ電機株式会社 | 電解水生成装置 |
| JPH11269686A (ja) | 1998-03-18 | 1999-10-05 | Permelec Electrode Ltd | 過酸化水素の製造方法及び過酸化水素製造用電解槽 |
| US20020025921A1 (en) * | 1999-07-26 | 2002-02-28 | Petito George D. | Composition and method for growing, protecting, and healing tissues and cells |
| US20030089618A1 (en) | 1998-04-10 | 2003-05-15 | Miz Co., Ltd. | Reducing electrolyzed water and method for producing same |
| CN1231994A (zh) | 1998-04-13 | 1999-10-20 | 王守林 | 家用臭氧水富氧水发生器 |
| JP3783150B2 (ja) * | 1998-04-24 | 2006-06-07 | 株式会社オメガ | 殺菌力を有する氷およびその製造方法 |
| US6126810A (en) | 1998-04-27 | 2000-10-03 | Steris Corporation | Generation of active chlorine in the presence of an organic load from sodium chloride in water |
| JPH11320259A (ja) | 1998-05-15 | 1999-11-24 | Michiko Suzuki | 放電加工方法及び該方法を実施するための装置 |
| JP2000042556A (ja) | 1998-05-28 | 2000-02-15 | Shimadzu Corp | 電解水製造装置 |
| RU2142917C1 (ru) | 1998-06-30 | 1999-12-20 | Попов Алексей Юрьевич | Способ и устройство для электрохимической обработки воды |
| US6368592B1 (en) | 1998-07-17 | 2002-04-09 | Massachusetts Institute Of Technology | Method of delivering oxygen to cells by electrolyzing water |
| US6458109B1 (en) | 1998-08-07 | 2002-10-01 | Hill-Rom Services, Inc. | Wound treatment apparatus |
| JP2000051858A (ja) | 1998-08-10 | 2000-02-22 | Osamu Miyake | 電解イオン水生成器 |
| US6033539A (en) | 1998-08-21 | 2000-03-07 | Gablenko; Viacheslav G. | Units for electro-chemical synthesis of water solution |
| JP2000070171A (ja) | 1998-08-26 | 2000-03-07 | Trp:Kk | 消毒用ウエットワイパーおよびその供給装置 |
| US6342150B1 (en) | 1998-09-09 | 2002-01-29 | Thomas Clay Sale | Redox water treatment system |
| JP2000084559A (ja) | 1998-09-09 | 2000-03-28 | Hideo Hayakawa | 水処理方法 |
| TW523547B (en) | 1998-10-05 | 2003-03-11 | Miz Co Ltd | Method of producing detergent and the apparatus thereof |
| US20030126710A1 (en) | 1998-11-09 | 2003-07-10 | Policicchio Nicola John | Cleaning composition, pad, wipe, implement, and system and method of use thereof |
| US6280594B1 (en) | 1998-12-01 | 2001-08-28 | Tateki Yamaoka | Device for producing ion water and partition wall for device for producing ion water |
| WO2000033757A1 (en) | 1998-12-09 | 2000-06-15 | Advanced H¿2?O Inc. | A system for decontamination of dental unit waterlines using electrolyzed water |
| JP2000189972A (ja) | 1998-12-28 | 2000-07-11 | Nippon Intek Kk | 酸化還元電位水、酸化還元電位水の製造装置、および添加物 |
| DE10011829C2 (de) | 1999-03-15 | 2002-08-08 | Nhk Spring Co Ltd | Stellantrieb für ein Fahrzeuginsassenrückhaltesystem |
| JP4583530B2 (ja) | 1999-03-19 | 2010-11-17 | オルガノ株式会社 | 熱交換用水及びその供給装置 |
| US6277266B1 (en) | 1999-03-23 | 2001-08-21 | Tateki Yamaoka | Device for producing ion water and partition wall for device for producing ion water |
| US6258225B1 (en) | 1999-03-23 | 2001-07-10 | Tateki Yamaoka | Device for producing ion water |
| US6436445B1 (en) * | 1999-03-26 | 2002-08-20 | Ecolab Inc. | Antimicrobial and antiviral compositions containing an oxidizing species |
| US7011940B1 (en) | 1999-04-14 | 2006-03-14 | Medical Discovery Partners Llc | Quality control for cytochemical assays |
| US20020006961A1 (en) | 1999-05-14 | 2002-01-17 | Katz Stanley E. | Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response |
| AU5331300A (en) | 1999-06-11 | 2001-01-02 | Henceforth Hibernia, Inc. | Prophylactic, therapeutic and industrial antioxidant compositions enhanced with stabilized atomic hydrogen/free electrons and methods to prepare and use such compositions |
| US6462250B1 (en) | 1999-06-22 | 2002-10-08 | Canon Kabushiki Kaisha | Method for decomposing halogenated aliphatic hydrocarbon compounds having adsorption process and apparatus for decomposition having adsorption means |
| DE60040317D1 (de) | 1999-06-30 | 2008-11-06 | Kao Corp | Keimtötende Reinigungsmittelzusammensetzung |
| ES2203377T3 (es) | 1999-06-30 | 2004-04-16 | Kao Corporation | Compuesto virucida y esporicida. |
| SE9902627D0 (sv) | 1999-07-08 | 1999-07-08 | Siemens Elema Ab | Medical nebulizer |
| DE60036582T2 (de) | 1999-08-06 | 2008-06-26 | Puricore International Ltd. | Elektrochemische Behandlung einer wässrigen Lösung |
| GB9918458D0 (en) | 1999-08-06 | 1999-10-06 | Sterilox Med Europ Ltd | Method and apparatus for the electrochemical processing of aqueous salt solutions |
| GB2355190B (en) | 1999-08-23 | 2004-07-28 | Sterilox Medical | Improvements in or relating to sterilising preparations |
| TW546257B (en) | 1999-09-01 | 2003-08-11 | Nihon Trim Co Ltd | Method and apparatus for producing electrolytic reduced water |
| JP2001079548A (ja) | 1999-09-16 | 2001-03-27 | Kaneko Agricult Mach Co Ltd | イオン水および酸化還元水製造装置 |
| US6852205B1 (en) | 1999-09-27 | 2005-02-08 | Shinko-Pantec Co., Ltd. | Water-electrolysis-device-use electrode plate, unit, solid electrolytic membrane unit and electrolytic cell |
| US6592907B2 (en) | 1999-10-04 | 2003-07-15 | Hampar L. Karagoezian | Synergistic antimicrobial ophthalmic and dermatologic preparations containing chlorite and hydrogen peroxide |
| JP2001113276A (ja) | 1999-10-14 | 2001-04-24 | Kaneko Agricult Mach Co Ltd | イオン水および酸化還元水製造装置 |
| US6333054B1 (en) | 1999-10-21 | 2001-12-25 | Amuchina S.P.A. | Topical, non-cytotoxic, antimicrobial hydrogel with thixotropic properties |
| JP2001139477A (ja) | 1999-11-17 | 2001-05-22 | Coherent Technology:Kk | 創傷部位の組織細胞増殖促進液 |
| US6340663B1 (en) | 1999-11-24 | 2002-01-22 | The Clorox Company | Cleaning wipes |
| CN1433270A (zh) | 1999-12-10 | 2003-07-30 | 花王株式会社 | 杀菌剂组合物 |
| US20030138498A1 (en) * | 1999-12-10 | 2003-07-24 | Kiyoaki Yoshikawa | Methods of sterilization |
| US6426066B1 (en) * | 2000-01-12 | 2002-07-30 | California Pacific Labs, Inc. | Use of physiologically balanced, ionized, acidic solution in wound healing |
| US20030185704A1 (en) | 2000-01-12 | 2003-10-02 | Suzanne Bernard | Physiologically balanced, ionized, acidic solution and methodology for use in wound healing |
| US7393522B2 (en) * | 2000-01-12 | 2008-07-01 | Novabay Pharmaceuticals, Inc. | Physiologically balanced, ionized, acidic solution and methodology for use in wound healing |
| JP4464027B2 (ja) | 2000-02-04 | 2010-05-19 | ラディカル ウォータース アイピー（ピーティーワイ）リミテッド | 歯科用装置および該装置の操作方法 |
| JP2004129314A (ja) | 2000-03-17 | 2004-04-22 | Soichi Sato | 蓄電装置を備えた熱電併給システム |
| JP4090665B2 (ja) * | 2000-04-11 | 2008-05-28 | ファースト・オーシャン株式会社 | 電解水製造方法 |
| IT1317329B1 (it) | 2000-04-13 | 2003-06-16 | Nottington Holding Bv | Calzatura traspirante. |
| JP3888835B2 (ja) | 2000-05-10 | 2007-03-07 | 花王株式会社 | 除菌消臭方法及び除菌消臭具 |
| JP3602773B2 (ja) | 2000-06-08 | 2004-12-15 | 株式会社ミクニ | 陽極電解水、及びその製造方法 |
| ES2228352T3 (es) | 2000-06-10 | 2005-04-16 | Degussa Ag | Procedimiento fotocatalitico. |
| WO2001096527A2 (en) * | 2000-06-14 | 2001-12-20 | Chanda Zaveri | Peptides with physiological activity |
| US20020023847A1 (en) | 2000-06-23 | 2002-02-28 | Shinichi Natsume | Cleansing system and method using water electrolysis |
| CN1449295A (zh) | 2000-07-07 | 2003-10-15 | 水基Ip股份有限公司 | 护理设备洗涤、消毒和/或灭菌的方法和设备 |
| US20020168418A1 (en) | 2000-08-04 | 2002-11-14 | H20 Technologies, Ltd. | Method and apparatus for treating water for use in improving the intestinal flora of livestock and poultry |
| DE10038457B4 (de) | 2000-08-07 | 2008-09-25 | Cognis Ip Management Gmbh | Verfahren zur Gewinnung von Sterinen und Tocopherolen |
| JP4607296B2 (ja) | 2000-08-08 | 2011-01-05 | ジャパンマテックス株式会社 | 還元水製造装置 |
| US6358395B1 (en) | 2000-08-11 | 2002-03-19 | H20 Technologies Ltd. | Under the counter water treatment system |
| JP3299250B2 (ja) | 2000-08-21 | 2002-07-08 | 修生 澄田 | 中間室を設けた純水電解槽 |
| JP2002079248A (ja) | 2000-09-06 | 2002-03-19 | Tominaga Oil Pump Mfg Co Ltd | 電解水生成装置 |
| KR100389917B1 (ko) | 2000-09-06 | 2003-07-04 | 삼성전자주식회사 | 산화성 물질을 포함하는 아노드 수 및/또는 환원성 물질을포함하는 캐소드 수를 사용하는 반도체 제조를 위한 습식공정 및 이 공정에 사용되는 아노드수 및/또는 캐소드수 |
| US20020032141A1 (en) | 2000-09-08 | 2002-03-14 | Gene Harkins | System and method to clean and disinfect hard surfaces using electrolyzed acidic water produced from a solution of NaCl |
| US6638364B2 (en) | 2000-09-08 | 2003-10-28 | Electric Aquagenics Unlimited | System to clean and disinfect carpets, fabrics, and hard surfaces using electrolyzed alkaline water produced from a solution of NaCl |
| EP1368848A2 (en) | 2000-09-28 | 2003-12-10 | Proton Energy Systems, Inc. | Regenerative electrochemical cell system and method for use thereof |
| US20020090428A1 (en) | 2000-10-12 | 2002-07-11 | Warf C. Cayce | Treatment fluid application apparatus for foodstuffs and methods related thereto |
| JP2002145787A (ja) | 2000-11-02 | 2002-05-22 | Kanebo Ltd | 外用剤 |
| KR100655834B1 (ko) | 2000-11-22 | 2006-12-08 | 오츠카 세이야쿠 가부시키가이샤 | Ｏ／ｗ형 유화 조성물 및 그의 조제 방법 |
| JP3805621B2 (ja) | 2000-12-19 | 2006-08-02 | 株式会社富永製作所 | 電解水生成装置 |
| US7122018B2 (en) | 2000-12-26 | 2006-10-17 | Sensormedics Corporation | Device and method for treatment of wounds with nitric oxide |
| JP2002201296A (ja) | 2000-12-28 | 2002-07-19 | Yunippu:Kk | プラスチック基材の表面改質方法 |
| US6540733B2 (en) | 2000-12-29 | 2003-04-01 | Corazon Technologies, Inc. | Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion |
| MXPA03006370A (es) | 2001-01-16 | 2004-12-02 | Tomco2 Equipment Company | Sistema de manejo de agentes patogenos. |
| US6620315B2 (en) | 2001-02-09 | 2003-09-16 | United States Filter Corporation | System for optimized control of multiple oxidizer feedstreams |
| US6844026B2 (en) | 2001-02-12 | 2005-01-18 | Rhodia Chimie | Preparation of particles by hydrolysis of a metal cation in the presence of a polymer |
| US7011739B2 (en) | 2001-03-22 | 2006-03-14 | Gene Harkins | Method for sanitizing shells of eggs using electrolyzed oxidizing water |
| US6921743B2 (en) | 2001-04-02 | 2005-07-26 | The Procter & Gamble Company | Automatic dishwashing compositions containing a halogen dioxide salt and methods for use with electrochemical cells and/or electrolytic devices |
| US6866756B2 (en) | 2002-10-22 | 2005-03-15 | Dennis Klein | Hydrogen generator for uses in a vehicle fuel system |
| WO2002081808A1 (en) | 2001-04-05 | 2002-10-17 | Sanyo Electric Co., Ltd. | Electric washing machine |
| US6767342B1 (en) | 2001-04-23 | 2004-07-27 | Evelyna D. Cantwell | Oxygen bandage system |
| GB2374819B (en) | 2001-04-27 | 2004-12-01 | Sterilox Tech Int Ltd | Oxidation-resistant coatings |
| JP2002338498A (ja) | 2001-05-17 | 2002-11-27 | Takeda Chem Ind Ltd | 内服用液剤 |
| TWI320713B (cg-RX-API-DMAC7.html) | 2001-06-01 | 2010-02-21 | Neochemir Inc | |
| JP3338435B2 (ja) | 2001-06-04 | 2002-10-28 | 修生 澄田 | 純水の電解による水素イオンまたは水酸イオンと酸化還元物質が共存した液の製造方法 |
| JP3619828B2 (ja) | 2001-06-21 | 2005-02-16 | 三洋電機株式会社 | 電解用電極及びその製造方法及び電解用電極を用いた電解方法及び電解水生成装置 |
| MXPA03011983A (es) | 2001-06-29 | 2004-03-26 | Miz Co Ltd | Metodo de antioxidacion y agua que funcionada como antioxidante. |
| KR20030005777A (ko) | 2001-07-10 | 2003-01-23 | 삼성전자 주식회사 | 전해이온수 및 희석된 ｈｆ용액을 동시에 사용하는 반도체세정 공정 |
| JP2003093479A (ja) | 2001-07-18 | 2003-04-02 | Sanyo Electric Co Ltd | 殺菌方法及び電解水生成装置 |
| US6656334B2 (en) | 2001-07-23 | 2003-12-02 | Skydon Corp. | Modified electrolysis cell and a housing for the same |
| WO2003010094A1 (en) | 2001-07-26 | 2003-02-06 | H20 Technologies, Ltd. | Apparatus and methods for cleaning and controlling bacteria growth in fluid supply lines |
| JP5140218B2 (ja) | 2001-09-14 | 2013-02-06 | 有限会社コヒーレントテクノロジー | 表面洗浄・表面処理に適した帯電アノード水の製造用電解槽及びその製造法、並びに使用方法 |
| WO2003024491A2 (en) | 2001-09-15 | 2003-03-27 | Icf Technologies, Inc. | Kits and methods for determining the effectiveness of sterilization or disinfection processes |
| US6833206B2 (en) | 2001-09-28 | 2004-12-21 | Daimlerchrysler Ag | Auxiliary power supply for a vehicle with a combustion engine and method for operating same |
| US20040171701A1 (en) | 2001-11-02 | 2004-09-02 | Technology Convergence Inc. | Methanol production process |
| EP1432427B1 (en) | 2001-10-01 | 2005-06-08 | Aquilabs S.A. | Composition of hypochlorous acid and its applications |
| US6756142B2 (en) | 2001-10-31 | 2004-06-29 | Motorola, Inc. | Fuel cell using non-linear positive temperature coefficient material |
| JP2003144001A (ja) | 2001-11-08 | 2003-05-20 | Hoshizaki Electric Co Ltd | 海洋生物の育成用水、育成用水の製造方法および製造装置 |
| US6833207B2 (en) | 2001-11-09 | 2004-12-21 | Hydrogenics Corporation | Unitized regenerative fuel cell with bifunctional fuel cell humidifier and water electrolyzer |
| WO2003042111A2 (en) | 2001-11-13 | 2003-05-22 | Radical Waters (Ip) (Pty) Limited | An electrochemical activation system suitable for producing electrochemically-activated solutions through use of an electrolytic cell exchange module |
| JP2003145153A (ja) | 2001-11-13 | 2003-05-20 | Sugano Minoru | 電解水の製造方法および製造装置 |
| EP1314699B1 (en) | 2001-11-23 | 2007-06-06 | Hoshizaki Denki Kabushiki Kaisha | Method for cleaning an electrolyzed water production apparatus |
| US6624135B2 (en) | 2001-11-26 | 2003-09-23 | S.C. Johnson & Son, Inc. | Cleaning sheet |
| AU2002353060A1 (en) | 2001-12-05 | 2003-06-17 | Oculus Innovative Sciences, Inc. | Method and apparatus for producing negative and positive oxidative reductive potential (orp) water |
| CN1803147B (zh) | 2001-12-11 | 2010-08-04 | 王小兵 | 缓冲剂对牙菌斑酸化的作用 |
| TW562673B (en) | 2001-12-14 | 2003-11-21 | Sanyo Electric Co | Foot warming bath device |
| US20050178920A1 (en) | 2002-01-22 | 2005-08-18 | Wilson Thomas R. | Spacecraft propulsion system |
| CA2446563A1 (en) | 2002-01-29 | 2003-08-07 | Mitsubishi Corporation | High-pressure hydrogen producing apparatus and producing method |
| JP3848882B2 (ja) | 2002-02-13 | 2006-11-22 | ニッポン高度紙工業株式会社 | 高イオン伝導性固体電解質及び該固体電解質を使用した電気化学システム |
| WO2003072510A1 (en) | 2002-02-20 | 2003-09-04 | H2O Technologies, Ltd. | Under the counter water treatment system |
| WO2003076688A2 (en) | 2002-03-06 | 2003-09-18 | The University Of Georgia Research Foundation, Inc. | Method and apparatus for electrolyzing water |
| US6733435B2 (en) | 2002-03-08 | 2004-05-11 | Canedo Luis | Electromagnetic method of treatment of lesions associated with inadequate blood perfusion, partial denervation, tissue loss, pain, edema, inflammation and infection |
| JP2003311270A (ja) | 2002-04-18 | 2003-11-05 | First Ocean Kk | 液体分配器 |
| CN1292842C (zh) | 2002-05-08 | 2007-01-03 | 株式会社三国 | 电解水喷雾装置 |
| KR100479627B1 (ko) | 2002-05-25 | 2005-04-06 | 유니셈 주식회사 | 폐가스 처리용 습식 전처리 장치 및 그 전처리 방법 |
| AU2003243534A1 (en) | 2002-06-10 | 2003-12-22 | Map Technologies Llc | Methods and devices for electrosurgical electrolysis |
| US6899903B2 (en) | 2002-06-25 | 2005-05-31 | Patrick Quillin | Composition for cleansing the sinuses |
| JP2004047827A (ja) | 2002-07-12 | 2004-02-12 | Mec Kk | プリント回路板の製造方法 |
| JP2004058006A (ja) | 2002-07-31 | 2004-02-26 | First Ocean Kk | 電解水製造方法 |
| US20040081705A1 (en) | 2002-09-18 | 2004-04-29 | Mana Gotou | Digestion promoter for ruminant animal and breeding method of ruminant animal |
| US20040055896A1 (en) | 2002-09-20 | 2004-03-25 | Sterilox Technologies, Inc. | Biocidal solution |
| US6843448B2 (en) | 2002-09-30 | 2005-01-18 | Daniel W. Parmley | Lighter-than-air twin hull hybrid airship |
| US6855233B2 (en) | 2002-11-15 | 2005-02-15 | Kinji Sawada | Apparatus for production of strong alkali and acid electrolytic solution |
| JP2004173628A (ja) | 2002-11-28 | 2004-06-24 | Fuso Pharmaceutical Industries Ltd | ヘモフィリスインフルエンザ菌の検出用プローブおよびそれを用いた方法 |
| DE602004032110D1 (de) | 2003-02-21 | 2011-05-19 | Avalence Llc | Elektrolyseapparatur und verfahren zur herstellung von wasserstoff |
| WO2004079840A2 (en) | 2003-02-28 | 2004-09-16 | Evat, Inc. | Three-dimensional flow-through electrode and electrochemical cell |
| EP1613793A4 (en) | 2003-03-04 | 2007-08-08 | Frs Waterware Inc D B A Waterw | ELECTROLYSIS CELL WITH HIGH-ELECTRIC FIELD |
| EP1617851A4 (en) | 2003-03-04 | 2011-09-21 | Frs Waterware Inc D B A Waterware Inc | SOLUTION WATER WITH FREE RADICALS |
| JP2004267956A (ja) | 2003-03-11 | 2004-09-30 | Mikuni Corp | 混合電解水の製造方法 |
| JP2004273961A (ja) | 2003-03-12 | 2004-09-30 | Ebara Corp | 金属配線形成基板の洗浄処理装置 |
| WO2004081515A2 (en) | 2003-03-13 | 2004-09-23 | Glaxosmithkline Biologicals S.A. | Purification process for bacterial cytolysin |
| WO2004081222A2 (en) | 2003-03-14 | 2004-09-23 | Sol-Gel Technologies Ltd. | Agent-encapsulating micro- and nanoparticles, methods for preparation of same and products containing same |
| US7014932B2 (en) | 2003-03-19 | 2006-03-21 | Proton Energy Systems, Inc. | Drainage system and process for operating a regenerative electrochemical cell system |
| AU2003901316A0 (en) | 2003-03-21 | 2003-04-03 | The Royal Alexandra Hospital For Children | Regulation of cell surface proteins |
| JP4041422B2 (ja) | 2003-03-26 | 2008-01-30 | ニッポン高度紙工業株式会社 | 固体電解質及び該固体電解質を使用した電気化学システム |
| GB2400611B (en) | 2003-04-15 | 2006-03-15 | Empower Corp H | An integrated renewable energy system |
| JP4040028B2 (ja) | 2003-04-16 | 2008-01-30 | 三洋電機株式会社 | 有機物と窒素化合物を含む被処理水の処理方法及び処理システム |
| US8912174B2 (en) | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
| JP2007502861A (ja) | 2003-05-01 | 2007-02-15 | レプリダイン・インコーポレーテッド | 抗菌方法及び組成物 |
| US20040226894A1 (en) | 2003-05-12 | 2004-11-18 | Tatsuo Okazaki | Method of preparing a sterile water containing hypochlorous or chlorous acid, package of sterile source materials, and sterile water preparation kit |
| WO2004103898A1 (en) | 2003-05-19 | 2004-12-02 | The Procter & Gamble Company | Compositions, devices and methods for stabilizing and increasing the efficacy of halogen dioxide solutions |
| US20040244537A1 (en) | 2003-06-05 | 2004-12-09 | Runyon Dale Leroy | Processing coal combustion products (CCP), ore, or other material using functionally electrolyzed water (FEW) |
| US6856916B2 (en) | 2003-06-13 | 2005-02-15 | Wen-Shing Shyu | Locating system of oxidation/reduction potential of electrolysis water and the constant output method of calibration and compensation thereof |
| US7453164B2 (en) | 2003-06-16 | 2008-11-18 | Polestar, Ltd. | Wind power system |
| US7445800B2 (en) | 2003-06-25 | 2008-11-04 | Eau Technologies, Inc. | Method for remediating mold and mildew using acidic electrolyzed water |
| KR100412258B1 (ko) | 2003-07-01 | 2003-12-31 | 주식회사 에스에프에이 | 오존수를 이용한 엘시디기판 세정방법 |
| ITPD20030166A1 (it) | 2003-07-22 | 2005-01-23 | Geox Spa | Suola traspirante ed impermeabile per calzature, particolarmente ma non esclusivamente per calzature di tipo aperto quali sandali, sabo' e simili e calzatura realizzata con detta suola |
| JP2005058848A (ja) * | 2003-08-08 | 2005-03-10 | Spring:Kk | 洗浄・消毒・創傷治癒に用いられる水の製造方法、その製造装置、及び洗浄・消毒・創傷治癒に用いられる水 |
| DK1656095T3 (en) | 2003-08-18 | 2014-03-10 | Novabay Pharmaceuticals Inc | N, N-DIHALOGENG-GENERATED AMINO ACIDS AND DERIVATIVES |
| US20050064259A1 (en) | 2003-09-24 | 2005-03-24 | Protonetics International, Inc. | Hydrogen diffusion electrode for protonic ceramic fuel cell |
| US20050067300A1 (en) | 2003-09-25 | 2005-03-31 | The Procter & Gamble Company | Electrolysis device for treating a reservoir of water |
| DE10349158A1 (de) | 2003-10-22 | 2005-06-16 | Airbus Deutschland Gmbh | Vorrichtung zur Wasserversorgung in Luftfahrzeugen |
| JP4653945B2 (ja) * | 2003-10-24 | 2011-03-16 | ミズ株式会社 | 薬理機能水、およびその用途 |
| GB0518826D0 (en) | 2005-09-15 | 2005-10-26 | Smith & Nephew | Apparatus with actives from tissue - exudialysis |
| JP4353772B2 (ja) | 2003-11-07 | 2009-10-28 | 三洋電機株式会社 | 電解水生成装置 |
| US20050101838A1 (en) | 2003-11-12 | 2005-05-12 | Camillocci Philip L. | Endoscope cover |
| GB0328124D0 (en) | 2003-12-04 | 2004-01-07 | Daly James | Membrane electrolyser with a two part end design |
| KR100542895B1 (ko) | 2003-12-22 | 2006-01-11 | 재단법인 포항산업과학연구원 | 차아염소산나트륨을 이용한 전해식 밸러스트수 처리방법및 처리장치 |
| US20050196462A1 (en) * | 2003-12-30 | 2005-09-08 | Oculus Innovative Sciences, Inc. | Topical formulation containing oxidative reductive potential water solution and method for using same |
| KR101249639B1 (ko) | 2003-12-30 | 2013-04-01 | 오클루스 이노바티브 사이언시즈 인코포레이티드 | 산화환원전위 수용액, 그의 제조방법 및 이를 사용하는방법 |
| US20050139808A1 (en) | 2003-12-30 | 2005-06-30 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and process for producing same |
| US9168318B2 (en) | 2003-12-30 | 2015-10-27 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and methods of using the same |
| US7374655B2 (en) | 2004-01-12 | 2008-05-20 | Novastron | Electrochemical water purifier |
| US7598299B2 (en) | 2004-02-03 | 2009-10-06 | Akzo Nobel Coatings International B.V. | Anti-fouling compositions comprising a polymer with salt groups |
| US20050178349A1 (en) | 2004-02-17 | 2005-08-18 | Tse Kwong W. | Multi-fueled internal combustion engine |
| US7510640B2 (en) | 2004-02-18 | 2009-03-31 | General Motors Corporation | Method and apparatus for hydrogen generation |
| FI20040279A7 (fi) | 2004-02-23 | 2005-08-24 | Pohjoisen Kantaperuna Oy | Menetelmä ja sovitelma juuresten pesemiseksi ja desinfioimiseksi |
| US7238272B2 (en) | 2004-02-27 | 2007-07-03 | Yoichi Sano | Production of electrolytic water |
| US7000395B2 (en) | 2004-03-11 | 2006-02-21 | Yuan Ze University | Hybrid clean-energy power-supply framework |
| US20050209518A1 (en) | 2004-03-17 | 2005-09-22 | Therafuse, Inc. | Self-calibrating body analyte monitoring system |
| JP2007530731A (ja) | 2004-03-23 | 2007-11-01 | ザ・クロロックス・カンパニー | 次亜塩素酸塩希釈方法 |
| US7157412B2 (en) | 2004-04-07 | 2007-01-02 | Advanced Medical Optics, Inc. | Alkylamine as an antimicrobial agent in ophthalmic compositions |
| US7758807B2 (en) | 2004-04-20 | 2010-07-20 | The Clorox Company | Microbial control with reduced chlorine |
| WO2005117914A2 (en) | 2004-06-04 | 2005-12-15 | Sterilox Technologies, Inc. | Biocidal solution |
| US20060008908A1 (en) | 2004-07-08 | 2006-01-12 | Giles Brian C | Method and composition for longevity assurance |
| EP1650329A3 (en) * | 2004-10-21 | 2007-11-07 | Trust Sterile Services Limited | Apparatus and method for electrolytic cleaning |
| DE102004056456A1 (de) | 2004-11-23 | 2006-05-24 | Eugen Malamutmann | Behandlungsvorrichtung für Wunden |
| US7749370B2 (en) | 2005-02-03 | 2010-07-06 | Osao Sumita | Manufacturing method of oxidative water to be employed for sterilization |
| EP1863502B1 (en) | 2005-03-23 | 2018-09-12 | Sonoma Pharmaceuticals, Inc. | Method of treating skin ulcers using oxidative reductive potential water solution |
| CN101163491B (zh) | 2005-03-23 | 2017-04-19 | 奥古露丝创新科学公司 | 利用氧化还原电位水溶液治疗皮肤溃疡的方法 |
| US20060241002A1 (en) | 2005-04-26 | 2006-10-26 | Rogozinski Wallace J | Sodium hypochlorite gel composition |
| US9498548B2 (en) | 2005-05-02 | 2016-11-22 | Oculus Innovative Sciences, Inc. | Method of using oxidative reductive potential water solution in dental applications |
| US20060263240A1 (en) * | 2005-05-06 | 2006-11-23 | Electric Aquagenics Unlimited | Electrolyzed water treatment for face and hands |
| US20060275387A1 (en) | 2005-06-03 | 2006-12-07 | BAGLEY David | Processed water and therapeutic uses thereof |
| US7648488B2 (en) | 2005-11-21 | 2010-01-19 | Pioneer Technology, Llc | Wound care system |
| EP1993571B1 (en) | 2006-01-20 | 2018-07-25 | Sonoma Pharmaceuticals, Inc. | Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution |
| US7779625B2 (en) | 2006-05-11 | 2010-08-24 | Kalypto Medical, Inc. | Device and method for wound therapy |
| US20080243096A1 (en) | 2006-10-05 | 2008-10-02 | Paul Svedman | Device For Active Treatment and Regeneration of Tissues Such as Wounds |
| US8273747B2 (en) | 2006-11-02 | 2012-09-25 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| WO2008089268A2 (en) | 2007-01-16 | 2008-07-24 | Puricore, Inc. | Methods and compositions for treating conditions associated with infection and/or inflammation |
| EP2130542A4 (en) | 2007-02-16 | 2010-06-02 | Taiko Pharmaceutical Co Ltd | BROAD SPECTRUM ANTIVIRAL COMPOSITION HAVING EXCELLENT STORAGE STABILITY |
| MX2009009760A (es) | 2007-03-13 | 2009-09-24 | Oculus Innovative Sciences Inc | Soluciones antimicrobiales que contienen monoxido de dicloro y metodos para hacer y utilizar las mismas. |
| US20090068255A1 (en) | 2007-04-30 | 2009-03-12 | Betty Yu | Use of matrix metalloproteinase inhibitors in skin care |
| KR101781229B1 (ko) | 2009-06-15 | 2017-09-22 | 오클루스 이노바티브 사이언시즈 인코포레이티드 | 차아염소산을 함유하는 용액 및 그의 사용 방법 |
| MX2012001415A (es) | 2009-07-30 | 2012-06-19 | Oculus Innovative Sciences Inc | Formulacion de hidrogel que comprende agua con potencial de oxidacion-reducció. |
-
2006
- 2006-03-23 EP EP06739816.4A patent/EP1863502B1/en not_active Not-in-force
- 2006-03-23 AU AU2006226750A patent/AU2006226750B2/en not_active Ceased
- 2006-03-23 AU AU2006226749A patent/AU2006226749B2/en not_active Ceased
- 2006-03-23 CA CA2602522A patent/CA2602522C/en active Active
- 2006-03-23 MX MX2007011709A patent/MX2007011709A/es active IP Right Grant
- 2006-03-23 ES ES06739816T patent/ES2701153T3/es active Active
- 2006-03-23 US US11/388,930 patent/US8840873B2/en active Active
- 2006-03-23 KR KR1020077024246A patent/KR101523091B1/ko not_active Expired - Fee Related
- 2006-03-23 US US11/388,912 patent/US8323252B2/en not_active Expired - Fee Related
- 2006-03-23 JP JP2008503290A patent/JP5816405B2/ja not_active Expired - Fee Related
- 2006-03-23 MX MX2007011706A patent/MX2007011706A/es active IP Right Grant
- 2006-03-23 CA CA2602411A patent/CA2602411C/en active Active
- 2006-03-23 KR KR1020077024245A patent/KR101532778B1/ko not_active Expired - Fee Related
- 2006-03-23 WO PCT/US2006/011251 patent/WO2006102680A2/en not_active Ceased
- 2006-03-23 BR BRPI0609429A patent/BRPI0609429B8/pt active IP Right Grant
- 2006-03-23 EP EP06739815.6A patent/EP1863501B1/en not_active Not-in-force
- 2006-03-23 BR BRPI0609711A patent/BRPI0609711B8/pt active IP Right Grant
- 2006-03-23 WO PCT/US2006/011252 patent/WO2006102681A2/en not_active Ceased
- 2006-03-23 JP JP2008503291A patent/JP5816406B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2602522C (en) | Method of treating skin ulcers using oxidative reductive potential water solution | |
| CA2606734C (en) | Method of using oxidative reductive potential water solution in dental applications | |
| CN101163491B (zh) | 利用氧化还原电位水溶液治疗皮肤溃疡的方法 | |
| AU2012241151B2 (en) | Method of using oxidative reductive potential water solution in dental applications | |
| HK1116342A (en) | Method of treating skin ulcers using oxidative reductive potential water solution | |
| HK1116342B (en) | Method of treating skin ulcers using oxidative reductive potential water solution | |
| HK1116340B (en) | Method of treating second and third degree burns using oxidative reductive potential water solution | |
| HK1123484B (en) | Method of using oxidative reductive potential water solution in dental applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |